{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:07:42Z","timestamp":1790478462291,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006559","name":"University of Tsukuba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.pbb.2022.173464","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T02:00:50Z","timestamp":1663034450000},"page":"173464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model"],"prefix":"10.1016","volume":"220","author":[{"given":"Takashi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2022.173464_bb0005","series-title":"Nature and Science of Sleep","first-page":"39","article-title":"New developments in the management of narcolepsy","volume":"9","author":"Abad","year":"2017"},{"issue":"10","key":"10.1016\/j.pbb.2022.173464_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","article-title":"Management of narcolepsy","volume":"18","author":"Barateau","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"10","key":"10.1016\/j.pbb.2022.173464_bb0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40263-017-0464-6","article-title":"Narcolepsy type 1 as an autoimmune disorder: evidence, and implications for pharmacological treatment","volume":"31","author":"Barateau","year":"2017","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pbb.2022.173464_bb0020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.neuroscience.2009.04.007","article-title":"Feeding-elicited cataplexy in orexin knockout mice","volume":"161","author":"Clark","year":"2009","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.pbb.2022.173464_bb0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0165-6147(99)01351-6","article-title":"Partial agonists and G protein-coupled receptor desensitization","volume":"20","author":"Clark","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.pbb.2022.173464_bb0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/jcph.143","article-title":"Electroencephalogram effects of armodafinil: comparison with behavioral alertness","volume":"53","author":"Conrado","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2022.173464_bb0035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"35","key":"10.1016\/j.pbb.2022.173464_bb0040","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.pbb.2022.173464_bb0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","article-title":"Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog","volume":"26","author":"Fujiki","year":"2003","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.pbb.2022.173464_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsmedchemlett.1c00626","article-title":"Discovery of TAK-925 as a potent, selective, and brain-penetrant orexin 2 receptor agonist","volume":"13","author":"Fujimoto","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.pbb.2022.173464_bb0055","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3949\/ccjm.85a.17086","article-title":"Narcolepsy: diagnosis and management","volume":"85","author":"Golden","year":"2018","journal-title":"Cleve. Clin. J. Med."},{"issue":"8","key":"10.1016\/j.pbb.2022.173464_bb0060","first-page":"RA177","article-title":"Modafinil for narcolepsy: systematic review and meta-analysis","volume":"16","author":"Golicki","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.pbb.2022.173464_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2019.102558","article-title":"Changes in excitability and ion channel expression in neurons of the major pelvic ganglion in female type II diabetic mice","volume":"220","author":"Gray","year":"2019","journal-title":"Auton. Neurosci."},{"issue":"2","key":"10.1016\/j.pbb.2022.173464_bb0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"issue":"22","key":"10.1016\/j.pbb.2022.173464_bb0075","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2022.173464_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.isci.2019.09.003","article-title":"Differential roles of each orexin receptor signaling in obesity","volume":"20","author":"Kakizaki","year":"2019","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.pbb.2022.173464_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","article-title":"An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-\/- mice and patients","volume":"30","author":"Lin","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.pbb.2022.173464_bb0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5664\/jcsm.6494","article-title":"Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy","volume":"13","author":"Maski","year":"2017","journal-title":"J. Clin. Sleep Med."},{"issue":"23","key":"10.1016\/j.pbb.2022.173464_bb0095","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1523\/JNEUROSCI.0499-13.2013","article-title":"Role of the medial prefrontal cortex in cataplexy","volume":"33","author":"Oishi","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2022.173464_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellsig.2017.01.024","article-title":"GPCR desensitization: acute and prolonged phases","volume":"41","author":"Rajagopal","year":"2018","journal-title":"Cell. Signal."},{"issue":"12","key":"10.1016\/j.pbb.2022.173464_bb0105","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","article-title":"CSF hypocretin\/orexin levels in narcolepsy and other neurological conditions","volume":"57","author":"Ripley","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pbb.2022.173464_bb0110","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41386-018-0168-8","article-title":"TAK-071, a novel M(1) positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects","volume":"44","author":"Sako","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2022.173464_bb0115","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2022.173464_bb0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"27","key":"10.1016\/j.pbb.2022.173464_bb0125","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pbb.2022.173464_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.pbb.2022.173464_bb0135","doi-asserted-by":"crossref","first-page":"e12684","DOI":"10.1111\/jsr.12684","article-title":"Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1","volume":"28","author":"Schinkelshoek","year":"2019","journal-title":"J. Sleep Res."},{"issue":"9211","key":"10.1016\/j.pbb.2022.173464_bb0140","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(05)74704-8","article-title":"Increased body-mass index in patients with narcolepsy","volume":"355","author":"Schuld","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.pbb.2022.173464_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2022.173464_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","article-title":"Recently approved and upcoming treatments for narcolepsy","volume":"34","author":"Thorpy","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pbb.2022.173464_bb0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.pbb.2022.173464_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2022.173464_bb0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.neuro.24.1.429","article-title":"To eat or to sleep? Orexin in the regulation of feeding and wakefulness","volume":"24","author":"Willie","year":"2001","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.pbb.2022.173464_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172794","article-title":"TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice","volume":"187","author":"Yukitake","year":"2019","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305722001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:43:12Z","timestamp":1758775392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305722001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"alternative-id":["S0091305722001435"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173464","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2022.173464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Takeda Pharmaceutical Company Limited. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"173464"}}